BacterioScan and Venatorx Pharmaceuticals believe that the combination of Venatorx’s novel antimicrobial compounds and BacterioScan’s rapid detection technologies could help speed new antibiotic drug discovery and development, reduce costs and support the global antibiotic stewardship mission.

Dr. Henkel has spent 20 years in the biopharmaceutical industry developing antibacterial, antifungal, antiviral, immunomodulatory and oncology drugs. He has successfully developed biologics, small molecules and natural products in the US and Europe.